Importantly, triptolide exerts potent antitumor effects by disrupting CARMA3-mediated ROS accumulation and ferroptosis suppression, highlighting its potential as a chemosensitizing agent in CARMA3-targeted therapeutic strategies for HCC. This evidence concerns the gene CARD10 and hepatocellular carcinoma.